SBIR/STTR Research Award

Extended preservation of human livers: a nature inspired, high subzero controlled, limited freezing approach

Award identifier 5c6168b85d01e5fbbdae26c207dd027c28a560b5e056853c12623a273e963b02Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$1,992,855

Program and phase

SBIR · Phase II

Award year

2022

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
SYLVATICA BIOTECH INC
Proposal award date
2022-09-26
Contract end date
2025-08-31
UEI
FJJVUJGDDLS3
Solicitation number
PA18-574
Topic code
300

Research abstract

ABSTRACT 1 in 5 liver waitlist patients do not receive a new liver in time, while many more patients are never listed but could benefit from liver replacement. While “bridge-to-transplant” technologies (ventricular assist devices and dialysis) have transformed the outlook for heart failure and kidney failure, no such treatment exists for patients with liver failure. Current liver sharing limits (approx. 500 miles) are based on limited preservation durations (6-10 hours). By extending preservation to just a few days we can enable nationwide (theoretically global) donor-recipient matching, allowing many livers that go untransplanted today (e.g. subsets of extended criteria donor livers that have been shown to offer substantial survival benefits) to be offered to the patients who most need them. Transplant surgeons have expressed excitement about this possibility, and it is thought that this achievement would have a profound impact on liver waitlist mortality. Among other benefits, this can also increase graft lifespan and reduce immunological rejection, eliminate the need for costly jet and helicopter transport, transform the practice of liver transplantation from emergency surgery to a flexibly scheduled procedure, and mitigate the severe disparities in liver transplantation. It will also allow immune tolerance induction protocols that have now achieved success in living donation to be adapted to the deceased donor context. To meet these needs, we will develop a comprehensive system for banking human livers for transplantation for periods of 5-7 days with a stretch goal of 10+ days or longer. We have created an integrated two-pronged approach to develop new stasis cocktails optimized for the critical phases of liver preservation: preconditioning and protection (prior to storage), preservation (during storage) and revival- resuscitation-repair (after storage). In parallel, we are creating devices for advanced perfusion, storage, and organ assessment before transplant decision. Our approach adapts the best strategies of freeze-tolerant and hibernating species, augmenting them with recent scientific and bioengineering advances. Importantly, we do not seek to solve all the problems of classical cryopreservation, but rather to be the first to develop preservation in thermodynamic equilibrium at high subzero (HSZ) temperatures (-10°C to -30°C), combined with programmed metabolic depression and enhanced stress tolerance. Feasibility of this approach has already been demonstrated; we have banked rat livers for 5 days at HSZ temperatures, and successfully preserved the first whole human liver lobe at -15°C. For this fast-track proposal, the Phase 1 goal will be to further refine our protocols and validate our initial unprecedented storage duration by banking rat livers for 5-7 days and using comprehensive post-preservation normothermic machine perfusion with functional assessment. We will also scale to whole human liver lobes, with subsequent hepatocyte isolation. Phase 2 will focus on optimizing key parameters that affect preservation outcomes in rat and human livers. Our goal is 6-10+ days of storage via (i) optimal modulation of ice growth, (ii) nature-inspired de-toxify/reenergize perfusion phase and (iii) precise control of thermodynamics using a prototype Bio-Thermodulator device.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

19 SBIR/STTR records share this UEI (2015–2024). Reported award amounts total $14,520,595. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, Department of Defense

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.